Part 4: The impact of the Inflation Reduction Act

Insights from Goldman Sachs and Parexel: Decoding Healthcare's Future: Investment, Clinical Research, and Regulatory Dynamics
How will the Inflation Reduction Act impact biopharma? What about the loss of patent exclusivity and its impact on product priorities? Will the increased scrutiny on M&A by the Federal Trade Commission slow down deal making? Learn what experts from Parexel and Goldman Sachs have to say on the topics.
For more expert insights, visit www.parexel.co...
January 2024, San Francisco CA
Disclaimer: The views and opinions that the panelists express are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs Asset Management for you to take any action.